The page is the record's research on the issuer — no analyst, no rating, no view.

CLNPHARMA (PLCLNPH00015) — research page

PL · pl-cm-kg/XWAR/PLCLNPH00015 · as of 2026-11-06

Identity and listing

The issuer is CLNPHARMA, listed on GPW Main Market under ticker PLCLNPH00015, with ISIN PLCLNPH00015 and LEI 259400Q0ERJT0NC5DT24. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.

fieldvaluesource · read date
nameCLNPHARMAsource · 2026-11-06
exchangeGPW Main Marketsource · 2026-11-06
tickerPLCLNPH00015source · 2026-11-06
ISINPLCLNPH00015source · 2026-11-06
LEI259400Q0ERJT0NC5DT24source · 2026-11-09
security typenot on the record
segmentnot on the record
sectornot on the record
jurisdictionnot on the record
statuslisted, not haltedsource · 2026-11-09

The disclosure read

The record holds 31 filings on 24 filing days in the window 2025-11-06 to 2026-11-06, of which 28 are ESPI Current, 2 are ESPI Quarterly and 1 is ESPI half years. The median gap between filing days is 9 days. The latest filing is an ESPI Current dated 2026-10-26, 11 days before the record date of 2026-11-06. The exchange median cadence gap is 8.0 days across 436 issuers, with a median of 31.0 filings and a median latency of 10 days. The sector peer comparison is not on the record for this market.

filingsmedian gap between filing daysdays from latest filing to as-of
this issuer31911
exchange median: GPW Main Market (436 issuers)31810
datetypecategoryfiling
2026-10-26ESPI CurrentESPI CurrentZakwalifikowanie projektu Celon Pharma S.A. do dofinansowania w ramach Programu "Fundusze Europejskie dla Nowoczesnej Gospodarki" - Ścieżka SMART
2026-10-21ESPI CurrentESPI CurrentZakwalifikowanie do dofinansowania dwóch projektów Celon Pharma S.A. w konkursie ogłoszonym przez Agencję Badań Medycznych [IGEN]
2026-10-16ESPI CurrentESPI CurrentZłożenie wniosków o wydanie pozwoleń na dopuszczenie do obrotu produktu leczniczego zawierającego semaglutyd w postaci roztworu do wstrzykiwań (projekt Reduzek, odpowiednik leku Ozempic).
2026-09-17ESPI half yearsESPI half yearssource
2026-09-10ESPI CurrentESPI CurrentUzyskanie pozytywnej opinii Jednostki Notyfikowanej (Notified Body Opinion) dla wstrzykiwacza stanowiącego element rozwoju produktu semaglutyd Celon Pharma (projekt Reduzek)

window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor and its location are not on the record. Auditor changes are not on the record, as this market's register has no lifecycle type map yet.

Events and halts

Listing, delisting, name change, domicile change and segment move are not on the record, as this market's register has no lifecycle type map yet. The halt flag shows listed, not halted.

Orderability

The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/pl/mifid-ii-product-governance/r1, with the chapter as of 2026-11-04.

rule acm-68000/pl/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

No research houses were found on the issuer's investor-relations page in the pages read.

Open research

One openly published research note is on the record, from Bell Potter Securities dated 2024-06-17.

datepublishernotekind
2024-06-17Bell Potter SecuritiesClinuvel Pharmaceuticals (CUV) — Looking to Vitiligoindependent

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

licensorentitlementtitledatesource
none loaded

As-of depth

The vintage is not sealed for this market. No issuer years are sealed, no market earliest sealed date is recorded, and the live record began date is not on the record.

Sources

7 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1
https://firds.esma.europa.eu/firds/ (identity.exchange)
10.2
https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
10.3
https://mcp.pl-cm-kg.ai/events/XWAR/PLCLNPH00015 (the disclosure lines)
10.4
https://www.gpw.pl/zawieszenia-i-wykluczenia (the halt flag)
10.5
https://pl.eu-cm-kg.ai/book/aio.json (the orderability chapter)
10.6
https://bellpotter.com.au/wp-content/uploads/2024/06/CUV-20240617.pdf (open research)
10.7
https://mcp.pl-cm-kg.ai/record/XWAR/PLCLNPH00015 (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"PLCLNPH00015"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:b5ddc0922d65f090.